Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development
- World’s first meningitis B national infant vaccination programme shows 75% drop in cases over three years
- US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Tweets from GSK
-
GSK @GSK
Today is a landmark in defining our approach and commitment to Global Health at GSK, as we announce licensing our #TB candidate vaccine to @GatesMRI for its continued development for developing countries where the TB burden is high. gsk.to/38AlZp0 #endTB
about 1 day ago
-
GSK @GSK
#NEWS Today, we announce our collaboration with @GatesMRI and @gatesfoundation for the continued development of our #TB candidate vaccine for low-income countries with high TB burden. Together we’re accelerating the fight to gsk.to/3aOgyV9 #endTB
about 1 day ago -
GSK @GSK
We've been named as a 2019 Equality Champion by @OFB_LGBT for our strong commitment to advancing #LGBT+ equality around the world. We couldn't be prouder of this recognition. Read more about how we are working to create a more equal world: gsk.to/2RRUaSh
about 1 day ago
